The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | Clonal interference of signaling mutations in AML: impacts on outcome
Raphael Itzykson, MD, PhD, of Hôpital Saint-Louis, Paris, France, discusses the clonal interference of signaling mutations in acute myeloid leukemia (AML). His group identified a subset of CBF-AML patients that harbor several signaling gene mutations, which arose in independent clones. Prof. Itzykson discusses the impacts of this clonal interference on long-term outcomes, and further research planned in this area. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
